Strumento inattivo

Altre lingue NextCell Pharma AB Nasdaq Stockholm

Azioni

SE0009723125

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

NextCell carries out a directed issue of units to guarantors in connection with the completed rights issue	03/07
NextCell's rights issue oversubscribed	17/06
The paediatric diabetes study gets the green light to treat the age group 7 - 11 years	12/06
Nextcell Pharma AB Receives Positive Recommendation from Data Safety Monitoring Board for Protrans-Young Study	12/06
The Board of Directors and management sign in addition to subscription commitments	11/06
NextCell publishes supplement to the prospectus regarding the rights issue	10/06
Cellaviva becomes an independent company under NextCell Pharma	05/06
NextCell procures top guarantee in ongoing rights issue	04/06
The subscription period in NextCell's rights issue commences today	31/05
NextCell publishes prospectus in connection with the rights issue of units of approximately SEK 40.1 million	30/05
Single treatment with ProTrans demonstrates long-term therapeutic effect over 5 years	28/05
NextCell Pharma AB Announces Single Treatment with ProTrans Demonstrates Long-Term Therapeutic Effect over 5 Years	28/05
Bulletin from the Extraordinary General Meeting of NextCell Pharma AB (publ)	27/05
Nextcell Pharma AB Elects Hans-Peter Ekre as New Chairman of the Board	27/05
NextCell publishes its Interim Report 2 2023/2024	25/04
NextCell Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	25/04
Notice of Extraordinary General Meeting in NextCell Pharma AB (publ)	24/04
The Board of Directors of NextCell resolves on a rights issue of units of approximately SEK 40.1 million, subject to approval by an Extraordinary General Meeting	24/04
NextCell's daughter company Cellaviva granted permission to handle amniotic tissue	22/04
NextCell Pharma AB Announces Swedish Health and Social Care Inspectorate Grants Their Cellaviva Tissue Establishment Permission to Handle Amniotic Tissue	22/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue NextCell Pharma AB Nasdaq Stockholm

Azioni

SE0009723125

Altre lingue

Filtri